Related content

Response to: Comment on ‘Effect of a low dose of gonadotropin releasing hormone antagonist on in vitro fertilization outcomes’ by Kerimoğlu et al.: Cetrorelix in COH cycles: time to re-evaluate the daily administered dose?

By Kerimoğlu Ozlem   Ercan Cihangir  

Archives of Gynecology and Obstetrics, Vol. 289, Iss. 4, 2014-04 ,pp. : 701-702

Springer Publishing Company

Access to resources Recommend Favorite

Cetrorelix® in women with poor ovarian response in previous assisted reproduction cycles

By Brook N.   Lavery S.   Margara R.   Trew G.  

Journal of Obstetrics & Gynaecology, Vol. 26, Iss. 3, 2006-04 ,pp. : 236-240

Informa Healthcare

Access to resources Recommend Favorite

Short Communication: FSH Time-Concentration Profiles Before and After Administration of 0.25 mg Cetrorelix in the GnRH-Antagonist Multiple-Dose Protocol for Ovarian Hyperstimulation

By Griesinger G.   Finas D.   Alisch A.   Roiha K.   Schultze-Mosgau A.   Schröder A. K.   Dafopoulos K.   Diedrich K.   Felberbaum R.  

Journal of Assisted Reproduction and Genetics, Vol. 21, Iss. 7, 2004-07 ,pp. : 279-282

Springer Publishing Company

Access to resources Recommend Favorite

Author response to Letter from Song et al.

By Song Ken   Musci Thomas   Caughey Aaron B.  

Journal of Maternal-Fetal and Neonatal Medicine, Vol. 27, Iss. 9, 2014-06 ,pp. : 972-972

Informa Healthcare

Access to resources Recommend Favorite

Role of rescue IVF-ET treatment in the management of high response in stimulated IUI cycles

By Olufowobi O   Sharif K   Papaioannou S   Mohamed H   Neelakantan D   Afnan M  

Journal of Obstetrics & Gynaecology, Vol. 25, Iss. 2, 2005-02 ,pp. : 166-168

Informa Healthcare

Access to resources Recommend Favorite